Keen Vision Acquisition Corporation Ordinary Shares (KVAC)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	40.50 k	40.50 k	40.50 k	40.50 k		40.50 k
Cash burn (monthly)	73.62 k	(no burn)	168.55 k	129.38 k		(no burn)
Cash used (since last report)	205.56 k	n/a	470.65 k	361.26 k		n/a
Cash remaining	-165.06 k	n/a	-430.15 k	-320.75 k		n/a
Runway (months of cash)	-2.2	n/a	-2.6	-2.5		n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2024

KVAC institutional ownership history Ownership history

21.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	10	5	+100.0%
Opened positions	6	3	+100.0%
Closed positions	1	22	-95.5%
Increased positions	2	1	+100.0%
Reduced positions	2	1	+100.0%

13F shares	Current	Prev Q	Change
Total value	20.68 bn	4.26 bn	+385.9%
Total shares	4.22 mm	553.38 k	+662.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Cowen And	2.34 mm	$8.06 bn	NEW
Schechter Investment Advisors	1.08 mm	$8.55 bn	+397.3%
CVI	262.28 k	$1.42 bn	NEW
Calamos Advisors	200.00 k	$1.05 bn	NEW
Spartan Fund Management	153.76 k	$8.29 mm	NEW
Wealthspring Capital	83.96 k	$673.62 mm	+350.3%
Warberg Asset Management	46.00 k	$480.70 mm	NEW
Dakota Wealth Management	31.10 k	$325.00 mm	-9.1%
TrueMark Investments	20.80 k	$109.36 mm	-13.3%
Context Capital Management	3.09 k	$167.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Cowen And	2.34 mm	+2.34 mm	NEW
Schechter Investment Advisors	1.08 mm	+860.28 k	+397.3%
CVI	262.28 k	+262.28 k	NEW
Wolverine Asset Management	0.00	-260.00 k	EXIT
Calamos Advisors	200.00 k	+200.00 k	NEW
Spartan Fund Management	153.76 k	+153.76 k	NEW
Wealthspring Capital	83.96 k	+65.32 k	+350.3%
Warberg Asset Management	46.00 k	+46.00 k	NEW
TrueMark Investments	20.80 k	-3.20 k	-13.3%
Dakota Wealth Management	31.10 k	-3.13 k	-9.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Medera Announces Publication Of Study Utilizing Machine Learning To Enhance Next-Generation Drug Screening With Human Mini-Heart Technology

31 Oct 24

Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs Human-specific diseases cannot be

Press releases

From Benzinga Pro

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

31 Oct 24

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

24 Oct 24

Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per yearHeart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases,